ERBB2 and breast cancer: HR-/HER2 + breast cancer accounts for about 15–20% of all breast cancers, and our study showed that AR positive rate was 72.2% in this type of breast cancer, and the log-rank test showed that AR-positive patients had poor prognosis, which was partially consistent with some previous studies [33, 34].